Full Breakdown
AI-Designed ‘Super-Antigen’ Vaccine Shows Safety in First Human Trial
6/5/2026, 8:42:57 AM
First Human Trial of an AI-Generated Universal Coronavirus Vaccine
The University of Cambridge, DIOSynVax and the University of Southampton completed a phase I trial of a DNA vaccine encoding an AI-designed “super-antigen”. The antigen targets the whole Sarbecovirus family, including SARS-CoV-2, SARS and related bat viruses. The dose was delivered needle-free by a micro-fluid jet.
Background: From Reactive to Proactive Vaccine Design
Traditional vaccines use antigens from a single strain, requiring updates as viruses mutate. Cambridge researchers applied machine-learning to thousands of coronavirus genomes, identified conserved structures, and let the AI generate a single “super-antigen” that could theoretically protect against the entire virus family.
Key Researchers and Partnerships
Prof. Jonathan Heeney (Cambridge) leads the effort; Prof. Saul Faust (Southampton) is chief investigator. Comments were provided by Prof. Andy Pollard (Oxford Vaccine Group) and Prof. Marian Knight (NIHR). DIOSynVax supplied the platform and University Hospital Southampton NHS Foundation Trust sponsored the trial.
Trial Design, Safety and Early Immunogenicity
The phase I study enrolled 49 participants (Irish News) or 39 participants (BBC), aged 18-50, receiving a single dose. No serious adverse events occurred. Antibody testing showed a modest rise against SARS-CoV-2, SARS and several bat coronaviruses. A phase II trial with >200 volunteers will assess dose response and durability.
Official Statements
Cambridge scientists said the work shifts vaccine design toward a proactive model, aiming to “get ahead of the curve”. Southampton highlighted the AI’s superior ability to design vaccines for rapidly changing viruses. The Oxford Vaccine Group called the data “fascinating”. NIHR’s director called the trial a “pivotal leap forward” for broad protection.
Conflicting Reports and Gaps
Sources differ on enrolment, reporting 49 versus 39 participants. Safety is uniformly confirmed, but immunogenicity is described as “modest” while researchers express “excitement”, indicating uncertainty about protective efficacy. No data on infection prevention or long-term immunity are available; larger trials are required.
Future Targets and Next Steps
The AI pipeline is being applied to universal seasonal flu, an H5N1 bird-flu candidate, and Ebola vaccines, including the bundibugyo strain causing the current outbreak in the Democratic Republic of Congo. A phase II trial with >200 volunteers will test multiple doses and durability, while parallel animal studies continue. Positive results could shape regulatory pathways for “future-proofed” vaccines.
Verbatim Quotes
- “We're always behind,” — Prof. Jonathan Heeney, University of Cambridge
- “what we're trying to do is get ahead of the curve” — Prof. Jonathan Heeney, University of Cambridge
- “What's really interesting is the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing.” — Prof. Saul Faust, University of Southampton
- “The remarkable success of this AI-designed ‘super-antigen’ trial marks a pivotal leap forward in our ability to deliver broad, lasting viral protection.” — Prof. Marian Knight, NIHR
